GSK

GSK plc ADR (GSK) | Rumor.io

GSK

Attention (50-day avg)0%

Attention rank (50-day avg)#1,302

Bullish sentiment (50-day avg)45%

Price to earnings ratio15.9

Market capitalization99.5B

Earnings per share3.11

Dividend yield (TTM)3.64%

Revenue (annual)32.7B

Net income (annual)6.3B

Social

What share of all stock conversation is about GSK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jul 23

GSK's $10.6B Nuvalent deal pays off early as FDA approves lung cancer drug Jideytro, GSK's first approved product for lung cancer.
GSK receives FDA approval for Jideytro (zidesamtinib) in ROS1+ NSCLC, backed by durable ARROS-1 trial responses, expanding GSK's targeted lung cancer franchise.
Spero Therapeutics' FDA approval for Utebzi (tebipenem pivoxil) is a major catalyst, with the drug expected to generate over $1B in sales, despite GSK's partnership and Spero's stock price drop.

Generated by AI

Sentiment

Of the messages about GSK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	48.57% +1.2	87.06% +0.87
Bearish	—	—	51.43% -1.2	12.94% -0.87

Bullish· Jan 20

$GSK's acquisition of RAPT Therapeutics for $2.2 billion at $58 per share provides a premium exit for RAPT shareholders and bolsters GSK's oncology footprint and access to promising late-stage assets.
The deal gives GSK access to RAPT's late-stage food allergy drug, ozureprubart, which could cut dosing to once every 12 weeks and has huge market potential with 17 million Americans affected.
GSK's diversified revenue base and strong HIV portfolio have driven a 42.8% gain over the past year, outpacing BMY's 3.1% decline, and promising new drug approvals and label expansions support solid growth prospects for GSK.

Bearish· Nov 11

$GSK was downgraded by UBS Group due to its losses.
The company's vaccine demand is not expected to increase despite breakthroughs in treatments, as UBS cut its rating to Sell.
UBS predicts a bottleneck in 2027 for $GSK, causing the stock to drop as it was cut to Sell.

Generated by AI

Topics

Of the messages about GSK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	94.12%	74.61%	53.11%
Macro	—	5.88%	10.34%	16.19%
Technical Analysis	—	0%	0.63%	7.14%
Earnings	—	0%	0%	13.78%
Analysts	—	0%	12.23%	8.06%
Controversies	—	0%	2.19%	1.72%

Earnings· Feb 1

GSK reported Q4 earnings that beat market expectations, with a 22% increase in EPS and a 3% decrease in revenue.
The company guided for double-digit earnings growth in 2023, with EPS expected to be between £1.56-1.60 and revenue between £31.08-31.66 billion.
GSK's Q4 sales and profit were ahead of expectations, with the company citing strong performance from its specialty medicines and vaccines businesses.

Analysts· Apr 5

Exane BNP Paribas upgraded GSK to Neutral from Underperform.
BNP Paribas and JPMorgan Chase & Co. have both reiterated a Neutral rating for GSK.
BNP Paribas set a price target of $37.20 for GSK following the upgrade to Neutral.

Announcements· Jun 17

GSK's ultra-long-acting biologic Exdensur has received two new China approvals for severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), with potential revenue of $4 billion.
The FDA has approved GSK's Utebzi (tebipenem pivoxil) for adults with complicated urinary tract infections (cUTIs), with availability expected by the end of 2026.
GSK predicts that Utebzi could be a game-changer for complicated UTIs, addressing over 3 million annual US cases and providing a critical new option for patients.

Controversies· Jun 23

GSK settles first lawsuit over cancer links to Zantac, avoiding a potentially costly US trial.
The settlement is seen as a positive development, with GSK's shares surging over 4% on the news.
Analysts estimate that the worst-case scenario for GSK in the Zantac litigation was a cost of "low hundreds of millions" of dollars.

Generated by AI

Community

Of the messages about GSK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	53.57%	55.99%	15.76%
Newcomers	—	46.43%	44.01%	84.24%

Regulars· Feb 2

Wave plans to pursue accelerated approval for WVE-006, an experimental oligonucleotide for alpha-1 antitrypsin deficiency, after GSK hands back rights to the genetic disease RNA editor.
GSK's decision to punt rights to WVE-006 allows Wave to accelerate its registrational strategy, according to Wave's CEO, who frames this move as a way for the company to move forward more quickly.
GSK will trim up to 350 jobs across US, UK R&D teams, as part of R&D changes, with the CEO favoring the US as the optimal location for pharma investment.

Newcomers· Jul 23

New investors are excited about the potential for high returns on stocks like GSK, with one individual aiming to make 50-75% per year by buying and selling GSK.
Some newcomers are using online platforms to participate in dividend challenges, where they invest a fixed amount and aim to earn a certain level of dividends, with one account having bought 20 companies one month ago.
The FDA approval of a new antibiotic, which is commercialized via GSK's partnership, has been seen as a major catalyst for Spero Therapeutics, but the stock has instead dropped, with one investor questioning if a cheaper buyout is a possibility.

Generated by AI

News

CDC data now show two measles deaths for 2026 (GSK:NYSE)

17h agoSeeking Alpha

GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?

Detailed price information for Sanofi-Aventis S.A. ADR (SNY-Q) from The Globe and Mail including charting and trades.

21h agoThe Globe and Mail

GSK retains ‘buy’ rating at Jefferies as B7H3 cancer programme seen as underappreciated

23h agoYahoo Finance

Berenberg Turns Bullish on GSK as its $750 Million Deal Adds to Pipeline Momentum

GSK plc (NYSE:GSK) has spent much of 2026 adding new drugs to its pipeline, and Berenberg is starting to think investors aren’t giving it enough credit. Berenberg analyst Kerry Holford upgraded GSK from Hold to Buy and raised the firm’s price target to 2,200p from 2,000p on September 15. Berenberg said it is “increasingly optimistic” […]

5d agoYahoo Finance

GSK Adds Another Cancer Drug in a $750 Million Deal. Is its Oncology Bet Getting Bigger?

GSK plc (NYSE:GSK) is adding another cancer drug to a pipeline that has been getting considerably more attention under CEO Luke Miels. The company has agreed to acquire full global rights to a trispecific T-cell engager from China-based Chimagen Biosciences in a deal worth up to $750 million. GSK (NYSE:GSK) plans to develop the experimental […]

5d agoYahoo Finance

GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity

On September 3, HUTCHMED (China) Limited (NASDAQ:HCM) announced an exclusive global development and licensing agreement with GSK plc (NYSE:GSK) for HMPL-A830, targeting colorectal, pancreatic, and lung cancers. Under the agreement, HUTCHMED receives a $110 million upfront payment, potential milestone payments up to $1.3 billion, and tiered royalties on net sales, while granting GSK worldwide rights […]

5d agoYahoo Finance

Also Discussed

Investors talking about GSK also mention

#	Name	Attention
1	Novartis AG Sponsored ADRNVS	0%-0.01
2	Sanofi ADRSNY	0%-0.01
3	AstraZeneca PLC American Depositary SharesAZN	0.02%+0.02
4	Bristol-Myers Squibb CompanyBMY	0.01%0
5	Merck & Co., Inc.MRK	0.01%-0.06
6	Amgen Inc.AMGN	0.01%+0
7	Pfizer Inc.PFE	0.04%-0.01
8	Gilead Sciences, Inc.GILD	0%-0.04
9	BioMarin Pharmaceutical IncBMRN	0%+0
10	Johnson & JohnsonJNJ	0%-0.06

GSK plc ADR

Healthcare
Drug Manufacturers - General

GSK plc ADR is an American depositary receipt representing two ordinary shares of GSK plc, a United Kingdom-based biopharmaceutical company. It provides U.S. investors with access to GSK’s healthcare business through a US-traded instrument tied to the company’s underlying ordinary shares. GSK focuses on pharmaceuticals, vaccines, and specialty medicines, with commercial activity centered on respiratory, immunology and inflammation, oncology, HIV, and infectious diseases. Its current portfolio includes products used in areas such as asthma, cancer, autoimmune disorders, and infectious disease prevention and treatment. The company operates through Commercial Operations and Research and Development, combining drug development with global commercialization of approved therapies. GSK plc ADR plays a role in the market as a widely followed healthcare security that reflects the performance of a multinational medicines and vaccines business with established reach across major therapeutic categories.

Website

Location

79 New Oxford Street

London, WC1A 1DG

United Kingdom

Social

What share of all stock conversation is about GSK?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jul 23

GSK's $10.6B Nuvalent deal pays off early as FDA approves lung cancer drug Jideytro, GSK's first approved product for lung cancer.
GSK receives FDA approval for Jideytro (zidesamtinib) in ROS1+ NSCLC, backed by durable ARROS-1 trial responses, expanding GSK's targeted lung cancer franchise.
Spero Therapeutics' FDA approval for Utebzi (tebipenem pivoxil) is a major catalyst, with the drug expected to generate over $1B in sales, despite GSK's partnership and Spero's stock price drop.

Generated by AI

Sentiment

Of the messages about GSK that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	48.57% +1.2	87.06% +0.87
Bearish	—	—	51.43% -1.2	12.94% -0.87

Bullish· Jan 20

$GSK's acquisition of RAPT Therapeutics for $2.2 billion at $58 per share provides a premium exit for RAPT shareholders and bolsters GSK's oncology footprint and access to promising late-stage assets.
The deal gives GSK access to RAPT's late-stage food allergy drug, ozureprubart, which could cut dosing to once every 12 weeks and has huge market potential with 17 million Americans affected.
GSK's diversified revenue base and strong HIV portfolio have driven a 42.8% gain over the past year, outpacing BMY's 3.1% decline, and promising new drug approvals and label expansions support solid growth prospects for GSK.

Bearish· Nov 11

$GSK was downgraded by UBS Group due to its losses.
The company's vaccine demand is not expected to increase despite breakthroughs in treatments, as UBS cut its rating to Sell.
UBS predicts a bottleneck in 2027 for $GSK, causing the stock to drop as it was cut to Sell.

Generated by AI

Topics

Of the messages about GSK that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	94.12%	74.61%	53.11%
Macro	—	5.88%	10.34%	16.19%
Technical Analysis	—	0%	0.63%	7.14%
Earnings	—	0%	0%	13.78%
Analysts	—	0%	12.23%	8.06%
Controversies	—	0%	2.19%	1.72%

Earnings· Feb 1

GSK reported Q4 earnings that beat market expectations, with a 22% increase in EPS and a 3% decrease in revenue.
The company guided for double-digit earnings growth in 2023, with EPS expected to be between £1.56-1.60 and revenue between £31.08-31.66 billion.
GSK's Q4 sales and profit were ahead of expectations, with the company citing strong performance from its specialty medicines and vaccines businesses.

Analysts· Apr 5

Exane BNP Paribas upgraded GSK to Neutral from Underperform.
BNP Paribas and JPMorgan Chase & Co. have both reiterated a Neutral rating for GSK.
BNP Paribas set a price target of $37.20 for GSK following the upgrade to Neutral.

Announcements· Jun 17

GSK's ultra-long-acting biologic Exdensur has received two new China approvals for severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps (CRSwNP), with potential revenue of $4 billion.
The FDA has approved GSK's Utebzi (tebipenem pivoxil) for adults with complicated urinary tract infections (cUTIs), with availability expected by the end of 2026.
GSK predicts that Utebzi could be a game-changer for complicated UTIs, addressing over 3 million annual US cases and providing a critical new option for patients.

Controversies· Jun 23

GSK settles first lawsuit over cancer links to Zantac, avoiding a potentially costly US trial.
The settlement is seen as a positive development, with GSK's shares surging over 4% on the news.
Analysts estimate that the worst-case scenario for GSK in the Zantac litigation was a cost of "low hundreds of millions" of dollars.

Generated by AI

Community

Of the messages about GSK, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	53.57%	55.99%	15.76%
Newcomers	—	46.43%	44.01%	84.24%

Regulars· Feb 2

Wave plans to pursue accelerated approval for WVE-006, an experimental oligonucleotide for alpha-1 antitrypsin deficiency, after GSK hands back rights to the genetic disease RNA editor.
GSK's decision to punt rights to WVE-006 allows Wave to accelerate its registrational strategy, according to Wave's CEO, who frames this move as a way for the company to move forward more quickly.
GSK will trim up to 350 jobs across US, UK R&D teams, as part of R&D changes, with the CEO favoring the US as the optimal location for pharma investment.

Newcomers· Jul 23

New investors are excited about the potential for high returns on stocks like GSK, with one individual aiming to make 50-75% per year by buying and selling GSK.
Some newcomers are using online platforms to participate in dividend challenges, where they invest a fixed amount and aim to earn a certain level of dividends, with one account having bought 20 companies one month ago.
The FDA approval of a new antibiotic, which is commercialized via GSK's partnership, has been seen as a major catalyst for Spero Therapeutics, but the stock has instead dropped, with one investor questioning if a cheaper buyout is a possibility.

Generated by AI

GSK

Social

Jul 23

Bullish· Jan 20

Bearish· Nov 11

Earnings· Feb 1

Analysts· Apr 5

Announcements· Jun 17

Controversies· Jun 23

Regulars· Feb 2

Newcomers· Jul 23

CDC data now show two measles deaths for 2026 (GSK:NYSE)

GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?

GSK retains ‘buy’ rating at Jefferies as B7H3 cancer programme seen as underappreciated

Berenberg Turns Bullish on GSK as its $750 Million Deal Adds to Pipeline Momentum

GSK Adds Another Cancer Drug in a $750 Million Deal. Is its Oncology Bet Getting Bigger?

GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity

Also Discussed

GSK plc ADR

Company Information

Location

CDC data now show two measles deaths for 2026 (GSK:NYSE)

GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential?

GSK retains ‘buy’ rating at Jefferies as B7H3 cancer programme seen as underappreciated

Berenberg Turns Bullish on GSK as its $750 Million Deal Adds to Pipeline Momentum

GSK Adds Another Cancer Drug in a $750 Million Deal. Is its Oncology Bet Getting Bigger?

GSK Bets on HUTCHMED to Expand its Multi-Billion-Dollar Oncology Opportunity

Also Discussed

Social

Jul 23

Bullish· Jan 20

Bearish· Nov 11

Earnings· Feb 1

Analysts· Apr 5

Announcements· Jun 17

Controversies· Jun 23

Regulars· Feb 2

Newcomers· Jul 23